Celldex Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CLDX Nasdaq 2836 www.celldex.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Celldex Therapeutics, Inc.

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 - Jun 14th, 2025 8:48 am
Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025 - Jun 12th, 2025 4:01 pm
Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue? - Jun 11th, 2025 9:30 am
Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress - Jun 10th, 2025 2:01 pm
Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors - Jun 6th, 2025 6:01 am
Celldex Therapeutics, Inc. (CLDX): Among the Best Cancer Stocks to Invest in for Long-Term Gain - May 9th, 2025 8:34 am
Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates - May 8th, 2025 3:10 pm
Celldex: Q1 Earnings Snapshot - May 8th, 2025 2:14 pm
Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update - May 8th, 2025 2:01 pm
Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease - May 5th, 2025 2:01 pm
Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last? - Mar 24th, 2025 1:24 pm
Celldex Therapeutics to Present at Upcoming Investor Conferences - Mar 4th, 2025 6:01 am
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025 - Mar 3rd, 2025 6:01 am
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025 - Mar 1st, 2025 10:45 am
Celldex Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line - Mar 1st, 2025 5:04 am
Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates - Feb 27th, 2025 3:30 pm
Celldex: Q4 Earnings Snapshot - Feb 27th, 2025 2:32 pm
Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update - Feb 27th, 2025 2:01 pm
Celldex Therapeutics And 2 Other Undervalued Small Caps With Insider Action In US - Jan 31st, 2025 3:02 am
Celldex Therapeutics (NASDAQ:CLDX) Is In A Good Position To Deliver On Growth Plans - Jan 29th, 2025 3:18 am